CYPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYPHERPUNK TECHNOLOGIES INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$2.53−0.04 (-1.56%)
Close on Oct 19, 2026
- Market cap
- $549.88M
- P/E (TTM)
- 36.1
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
13.6%
15M of 108M shares
Institutional holders
47
13 new, 5 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 9 sales
Net sold $6.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Severns Sean Michael | 6,000,000 | 10.59% | 13G (passive) | Nov 12, 2025 |
| Winklevoss Capital Fund, LLC | 24,854,613 | 19.90% | 13D (active) amendment | Aug 17, 2026 |
| Winklevoss Capital Management, LLC | 12,084,463 | 19.90% | 13D (active) | Oct 8, 2025 |
| Winklevoss Treasury Investments, LLC | 12,084,463 | 19.90% | 13D (active) amendment | Oct 8, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CYPH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 3,887,574 | 3.61% | $2.38M | +2,069,160 | 0.00% |
| BlackRock, Inc. | 2,622,823 | 2.43% | $1.61M | +280,649 | 0.00% |
| Jane Street Group, LLC | 1,701,926 | 1.58% | $1.04M | New | 0.00% |
| Geode Capital Management, LLC | 1,173,737 | 1.09% | $718.80K | +602,669 | 0.00% |
| UBS Group AG | 1,127,366 | 1.05% | $689.95K | +956,298 | 0.00% |
| Citadel Advisors LLC | 836,153 | 0.78% | $511.98K | New | 0.00% |
| XTX Topco Ltd | 638,329 | 0.59% | $390.85K | +607,671 | 0.01% |
| Vanguard Fiduciary Trust Co | 571,345 | 0.53% | $349.66K | +274,259 | 0.00% |
| State Street Corp | 516,113 | 0.48% | $316.02K | +376,000 | 0.00% |
| Northern Trust Corp | 222,031 | 0.21% | $135.95K | +134,469 | 0.00% |
| Susquehanna International Group, Llp | 217,997 | 0.20% | $133.48K | −44,956 | 0.00% |
| Morgan Stanley | 174,586 | 0.16% | $106.90K | +137,081 | 0.00% |
| LPL Financial LLC | 159,194 | 0.15% | $97.47K | −3,300 | 0.00% |
| Sequoia Financial Advisors, LLC | 152,500 | 0.14% | $93.38K | +104,500 | 0.00% |
| HighTower Advisors, LLC | 100,580 | 0.09% | $61.59K | +40,080 | 0.00% |
| Virtu Financial LLC | 86,789 | 0.08% | $53 | +76,601 | 0.00% |
| Two Sigma Investments, LP | 80,411 | 0.07% | $49.24K | +13,839 | 0.00% |
| Key Client Fiduciary Advisors, LLC | 75,102 | 0.07% | $45.99K | −5,322 | 0.01% |
| Farther Finance Advisors, LLC | 44,844 | 0.04% | $27.46K | +42,786 | 0.00% |
| Texas Capital Bank Wealth Management Services Inc | 37,600 | 0.03% | $23.02K | −66,600 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 47 | 15M | 13.6% | 13 / 16 | 6 / 5 | 8M | 1M |
| Q1 2026 | 40 | 7M | 6.8% | 12 / 5 | 8 / 9 | 3M | 3M |
| Q4 2025 | 38 | 9M | 8.0% | 13 / 13 | 7 / 8 | 6M | 10M |
| Q3 2025 | 33 | 13M | 11.8% | 2 / 8 | 7 / 12 | 2M | 3M |
| Q2 2025 | 43 | 14M | 12.8% | 6 / 10 | 12 / 8 | 1M | 4M |
| Q1 2025 | 45 | 17M | 15.5% | 11 / 9 | 14 / 23 | 2M | 5M |
| Q4 2024 | 57 | 19M | 17.8% | 15 / 20 | 9 / 6 | 8M | 4M |
| Q3 2024 | 48 | 15M | 13.8% | 11 / 9 | 12 / 8 | 1M | 1M |
| Q2 2024 | 46 | 15M | 13.7% | 8 / 18 | 9 / 6 | 7M | 1M |
| Q1 2024 | 44 | 8M | 7.9% | 11 / 12 | 9 / 9 | 3M | 1M |
| Q4 2023 | 43 | 7M | 6.4% | 9 / 14 | 10 / 8 | 1M | 2M |
| Q3 2023 | 42 | 8M | 7.2% | 10 / 13 | 7 / 5 | 2M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CYPH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,630,994 | 2.44% | $1.61M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,148,035 | 1.07% | $702.94K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 264,741 | 0.25% | $299.16K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 89,230 | 0.08% | $100.83K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 76,899 | 0.07% | $47.09K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 71,448 | 0.07% | $80.74K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 52,280 | 0.05% | $59.08K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 31,646 | 0.03% | $19.38K | 0.00% | Jun 30, 2026 |
| Simplify Health Care ETF | 27,979 | 0.03% | $17.13K | 0.00% | Jun 30, 2026 |
| Victory Extended Market Index Fund | 9,914 | 0.01% | $5.86K | 0.00% | Jul 31, 2026 |
| Total Stock Market Index Trust | 1,572 | 0.00% | $963 | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -2,100 | -0.00% | -$1.29K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| William Patrick McEvoy III | Chief Investment Officer, Director, 10% owner | 24,854,613 | 23.06% | Aug 19, 2026 |
| Douglas E. Onsi | CEO,CFO,Pres.,GC,Treas.&Sec., Director | 106,858 | 0.10% | Jul 2, 2026 |
| Kevin Zhang | Head of Mining | 330,904 | 0.31% | Aug 24, 2026 |
| John Mark O'Mahony | Chief Manufacturing Officer | 27,500 | 0.03% | Jul 1, 2025 |
| Augustine Lawlor | Chief Operating Officer | 706,042 | 0.66% | Jul 1, 2025 |
| Jason Baum | Chief Scientific Officer | 15,896 | 0.01% | Jul 1, 2025 |
| Christine Granfield | VP, Head of Reg Affairs/Qual | 22,500 | 0.02% | Apr 1, 2025 |
| Cynthia Sirard | Chief Medical Officer | 27,500 | 0.03% | Apr 1, 2025 |
| Patricia A. Martin | Director | 118,750 | 0.11% | Sep 25, 2026 |
| Khing Djien Oei | Director | 0 | – | Sep 25, 2026 |
| Amanda Fabiano | Director | – | – | Sep 25, 2026 |
| Thomas John Dietz | Director | 132,500 | 0.12% | Aug 27, 2026 |
| Nissim Mashiach | Director | 168,750 | 0.16% | Jul 2, 2026 |
| William Li | Director | 74,700 | 0.07% | Jul 2, 2026 |
| Christian M. Richard | Director | 74,700 | 0.07% | Jul 2, 2026 |
| Christopher Mirabelli | Director | 130,376 | 0.12% | Mar 30, 2026 |
| Richard Schilsky | Director | 74,700 | 0.07% | Mar 17, 2026 |
| James H. Cavanaugh | Director | 168,963 | 0.16% | Mar 17, 2026 |
| Joseph Loscalzo | Director | 168,750 | 0.16% | Mar 17, 2026 |
| Tyler Howard Winklevoss | 10% owner | 24,854,613 | 23.06% | Aug 19, 2026 |
| Cameron Howard Winklevoss | 10% owner | – | – | Aug 19, 2026 |
| Winklevoss Treasury Investments, LLC | 10% owner | – | – | Aug 19, 2026 |
| Winklevoss Capital Fund, LLC | 10% owner | – | – | Aug 19, 2026 |
| Winklevoss Capital Management, LLC | 10% owner | 8,283,761 | 7.69% | Aug 19, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Khing Djien Oei Director | Sep 25, 2026 | Sale | −168,750 | $3.92 | $661.50K | 0 |
| Patricia A. Martin Director | Sep 23, 2026 | Sale | −50,000 | $3.86 | $193.00K | 118,750 |
| Thomas John Dietz Director | Aug 26, 2026 | Sale | −20,000 | $1.72 | $34.40K | 132,500 |
| William Patrick McEvoy III Chief Investment Officer, Director, 10% owner | Aug 17, 2026 | Option exercise | +16,570,852 | – | – | 24,854,613 |
| Tyler Howard Winklevoss 10% owner | Aug 17, 2026 | Option exercise | +16,570,852 | – | – | 24,854,613 |
| Christopher Mirabelli Director | Mar 26, 2026 | Sale | −60,000 | $0.71 | $42.60K | 130,376 |
| Nissim Mashiach Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,750 |
| Nissim Mashiach Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,700 |
| Khing Djien Oei Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,700 |
| Khing Djien Oei Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,750 |
| James H. Cavanaugh Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,963 |
| James H. Cavanaugh Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,913 |
| Patricia A. Martin Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,750 |
| Patricia A. Martin Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,700 |
| Christian M. Richard Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,700 |
| Christian M. Richard Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,750 |
| Richard Schilsky Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,700 |
| Richard Schilsky Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,750 |
| Christopher Mirabelli Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 190,376 |
| Christopher Mirabelli Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 96,326 |
| William Li Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,700 |
| William Li Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,750 |
| Thomas John Dietz Director | Mar 13, 2026 | Option exercise | +104,500 | – | – | 152,500 |
| Joseph Loscalzo Director | Mar 13, 2026 | Option exercise | +94,050 | – | – | 168,750 |
| Joseph Loscalzo Director | Mar 13, 2026 | Option exercise | +74,700 | – | – | 74,700 |
| Thomas John Dietz Director | Dec 26, 2025 | Option exercise | +83,000 | – | – | 83,000 |
| Thomas John Dietz Director | Dec 26, 2025 | Tax withholding | −35,000 | $1.20 | $42.00K | 48,000 |
| Christopher Mirabelli Director | Dec 23, 2025 | Other | +712 | – | – | 21,626 |
| Christopher Mirabelli Director | Dec 23, 2025 | Other | −2,136 | – | – | 0 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.&Sec., Director | Dec 23, 2025 | Other | −2,136 | – | – | 0 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.&Sec., Director | Dec 23, 2025 | Other | +712 | – | – | 106,858 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.&Sec., Director | Nov 17, 2025 | Sale | −261,840 | $3.14 | $822.18K | 416,616 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.&Sec., Director | Nov 17, 2025 | Sale | −414,479 | $3.14 | $1.30M | 2,136 |
| Christopher Mirabelli Director | Nov 17, 2025 | Sale | −261,840 | $3.14 | $822.18K | 416,616 |
| Christopher Mirabelli Director | Nov 17, 2025 | Sale | −414,479 | $3.14 | $1.30M | 2,136 |
| James H. Cavanaugh Director | Nov 17, 2025 | Sale | −261,840 | $3.14 | $822.18K | 0 |
| Augustine Lawlor Chief Operating Officer | Mar 28, 2025 | Option exercise | +22,500 | – | – | 27,586 |
| Augustine Lawlor Chief Operating Officer | Mar 28, 2025 | Tax withholding | −7,797 | $0.32 | $2.50K | 19,789 |
| Christine Granfield VP, Head of Reg Affairs/Qual | Mar 28, 2025 | Option exercise | +22,500 | – | – | 22,500 |
| Christine Granfield VP, Head of Reg Affairs/Qual | Mar 28, 2025 | Tax withholding | −6,604 | $0.32 | $2.11K | 15,896 |
| Cynthia Sirard Chief Medical Officer | Mar 28, 2025 | Option exercise | +22,500 | – | – | 27,500 |
| Christopher Mirabelli Chairman of the Board, Director | Mar 28, 2025 | Tax withholding | −6,672 | $0.32 | $2.14K | 20,914 |
| Christopher Mirabelli Chairman of the Board, Director | Mar 28, 2025 | Option exercise | +22,500 | – | – | 27,586 |
| Jason Baum Chief Scientific Officer | Mar 28, 2025 | Tax withholding | −6,604 | $0.32 | $2.11K | 15,896 |
| Jason Baum Chief Scientific Officer | Mar 28, 2025 | Option exercise | +22,500 | – | – | 22,500 |
| John Mark O'Mahony Chief Manufacturing Officer | Mar 28, 2025 | Option exercise | +22,500 | – | – | 27,500 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.&Sec., Director | Mar 28, 2025 | Option exercise | +32,500 | – | – | 106,146 |
| Christopher Mirabelli Chairman of the Board, Director | Nov 13, 2024 | Option exercise | +2,136 | $2.82 | $6.02K | 678,456 |
| Augustine Lawlor Chief Operating Officer | Nov 13, 2024 | Option exercise | +2,136 | $2.82 | $6.02K | 678,456 |
| James H. Cavanaugh Director | Nov 13, 2024 | Option exercise | +213 | $2.82 | $601 | 213 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.&Sec., Director | Nov 13, 2024 | Option exercise | +2,136 | $2.82 | $6.02K | 678,456 |
| John Mark O'Mahony Chief Manufacturing Officer | Jan 26, 2024 | Option exercise | +5,000 | – | – | 5,000 |
| Augustine Lawlor Chief Operating Officer | Jan 26, 2024 | Option exercise | +5,000 | – | – | 5,086 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.,&Sec., Director | Jan 26, 2024 | Option exercise | +7,500 | – | – | 73,646 |
| Cynthia Sirard Chief Medical Officer | Jan 26, 2024 | Option exercise | +5,000 | – | – | 5,000 |
| Christopher Mirabelli Chairman of the Board, Director | Jan 26, 2024 | Option exercise | +5,000 | – | – | 5,086 |
| Douglas E. Onsi CEO,CFO,Pres.,GC,Treas.,&Sec., Director | Mar 17, 2023 | Option exercise | +660,606 | – | – | 661,466 |
| BeiGene, Ltd. 10% owner | Sep 24, 2021 | Buy | +2,543,800 | $2.85 | $7.25M | 7,348,437 |
| HealthCare Partners VIII, L.P. 10% owner | Dec 28, 2020 | Other | −2,618,406 | – | – | 0 |
| Life Sciences Master Fund Ltd Perceptive 10% owner | Jun 22, 2020 | Buy | +1,750,000 | $2.00 | $3.50M | 8,476,496 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Thomas John Dietz Director | Aug 26, 2026 | 20,000 | $32.30K | Aug 26, 2026 | Restricted Stock Unit |
| Mirabelli Christopher Director | Mar 27, 2026 | 60,000 | $42.63K | Mar 26, 2026 | RSU Settlement |